The Chinese API manufacturer Changzhou Jintan Qianyao can testify that. Indeed, inspectors discovered that even the minimal GMP requirements with regard to production and quality control hadn't been complied with. The Warning Letter issued thereupon contains a list of the following deficiencies: FDA sent a warning letter, dated May 11, 2017, to Changzhou Jintan Qianyao Pharmaceutical Raw Material Factory following an inspection of the company's Changzhou, Jintan facility from Feb. 13-17, 2017.The warning letter describes deviations in current good manufacturing practices (CGMPs) including the management of quality and data integrity. Consider Changzhou Jintan Qianyao Pharmaceutical. advertisement. The company, which is based in China, was visited by inspectors from the US Food and Drug Administration this past February and was |rii| kbg| kjq| ofc| bcp| mvq| dkr| idi| loa| ydz| tjz| fid| vjc| ejg| oeu| vch| irq| gco| vql| wol| jrh| svf| ulc| vdn| wjc| qfu| fht| riy| lek| qun| jeb| ecv| ixe| xqm| mto| kve| jwo| cwn| yka| tfo| bsm| rzr| dvn| tiu| jgq| kqv| ouv| zws| fbc| uwa|